Botulinum Toxin

Botulinum toxin is a potent neurotoxic protein produced by the bacterium Clostridium botulinum. In concentrated form the natural toxin is the agent responsible for botulism, a serious form of paralysis. In tightly controlled, highly diluted pharmaceutical preparations, however, purified botulinum toxin is an approved medicine marketed under brand names such as Botox, Dysport, Xeomin, and Jeuveau.

Unlike most peptides discussed in this reference, botulinum toxin is a well-established regulated drug with formal approvals from agencies including the U.S. FDA. The distinction that matters most is between the raw toxin, which is among the most poisonous naturally occurring substances known, and the standardized, unit-controlled clinical product administered by trained professionals.

Botulinum toxin acts at the junction between nerves and muscle by interfering with the release of the neurotransmitter acetylcholine. Broadly, its mechanistic themes include:

• Cleaving proteins (the SNARE complex, such as SNAP-25) that nerve endings need to release acetylcholine
• Preventing the chemical signal that tells a muscle to contract, producing temporary, localized muscle relaxation or paralysis
• Acting on secretory nerves as well, which underlies uses for excessive sweating and certain glandular conditions

The effect is temporary because nerve terminals gradually recover and form new connections, so clinical effects wane over a period of months. Because the toxin blocks a fundamental signaling step, effects are dose-dependent and can be serious if the toxin spreads beyond the intended site.

Botulinum toxin is approved for a wide range of cosmetic and medical purposes. Cosmetic use is best known for the temporary softening of certain facial lines. Medical uses studied and approved in various regions include chronic migraine, cervical dystonia and other muscle-spasticity conditions, excessive sweating (hyperhidrosis), certain overactive bladder conditions, and some eye-muscle disorders.

These uses are established within regulated clinical practice, where dosing is standardized in product-specific units and administration is performed by trained clinicians. Approval status and specific indications vary by country and by the particular product, since different formulations are not interchangeable.

Botulinum toxin is not classified as a performance-enhancing substance and is not named on the World Anti-Doping Agency (WADA) Prohibited List. It is used therapeutically for muscle-relaxing and other medical indications rather than to enhance athletic performance.

Athletes should nonetheless confirm current status directly with their sport's governing body and the latest WADA list, and follow any therapeutic use documentation requirements, since regulatory positions can change.

Within approved clinical use, commonly described effects include local injection-site reactions, temporary bruising, headache, and — depending on the treatment area — unintended weakness of nearby muscles, such as eyelid drooping. Regulators have issued warnings that, in rare cases, effects of the toxin may spread away from the injection site, producing symptoms such as difficulty swallowing, speaking, or breathing.

These serious risks make professional training, accurate product handling, and proper patient selection essential. Counterfeit or unregulated products carry additional, unpredictable danger.

Botulinum toxin products are measured in product-specific potency units rather than by simple weight, and these units are not interchangeable between different brands or formulations.

Any dosing is the responsibility of a licensed clinician working from the specific approved product label. This section is conceptual only and does not constitute medical advice.

Marketed botulinum toxin products divide first by serotype and then by how the neurotoxin is packaged. Type A dominates the market:

• onabotulinumtoxinA — Botox and Botox Cosmetic (AbbVie/Allergan), supplied as a vacuum-dried neurotoxin complex in 50, 100, and 200 Unit vials.
• abobotulinumtoxinA — Dysport (Ipsen/Galderma), lyophilized powder.

• incobotulinumtoxinA — Xeomin (Merz). The complex is purified and the hemagglutinin and non-hemagglutinin accessory proteins stripped away, leaving the 150 kDa neurotoxin alone (Xeomin prescribing information).

• prabotulinumtoxinA — Jeuveau (Evolus), approved only for glabellar lines; its label states plainly that it is not approved for spasticity or any condition other than glabellar lines.

• daxibotulinumtoxinA — Daxxify (Revance), also a an accessory-protein-free 150 kDa toxin, but stabilised with a 35-amino-acid peptide excipient (RTP004) instead of relying on human albumin (Daxxify prescribing information).

• rimabotulinumtoxinB — Myobloc (Solstice), the one marketed type B product, supplied as a ready-to-use solution rather than a powder.

The critical formulation fact is that potency is defined by assay, not by mass. One Unit of Botox Cosmetic corresponds to the calculated median intraperitoneal lethal dose in mice under that manufacturer's specific assay conditions, and the specific activity is roughly 20 Units per nanogram of neurotoxin complex (Botox Cosmetic prescribing information). Because each manufacturer runs its own assay with its own vehicle and dilution scheme, Units are brand-specific by construction. There is no published conversion factor, and the labels explicitly refuse to supply one.

These products are also not combined with each other in practice. What varies between them is accessory protein content, diluent, storage, and reconstitution — handling differences that matter enough that they are treated as separate medicines rather than substitutable versions of one drug.

Botulinum toxin has a substantial, mature evidence base spanning decades of clinical use across cosmetic and medical indications. This is a notable contrast with most experimental peptides, whose evidence is far thinner.

Ongoing research continues to explore additional therapeutic applications, longer-acting or more targeted formulations, and refinements in technique. Even with an established evidence base, appropriate use depends on trained clinical judgment rather than general summaries.

For deeper dives on this substance, see:

• Botulinum toxin benefits and areas of interest
• Botulinum toxin side effects and safety context
• Botulinum toxin dosing concepts (educational)
• Botulinum toxin research and evidence overview

Is Botox a peptide? No, and the difference is not a technicality. Botulinum neurotoxin type A is a bacterial protein of 1,296 amino acids with a mass of about 149 kDa, produced by Clostridium botulinum and cut into a light chain and a heavy chain joined by a disulfide bond (UniProt P0DPI1). Research peptides are typically 3–40 residues of synthetic chemistry; this is a fermented bacterial enzyme roughly thirty times that size. It appears in peptide catalogs because of the injectable-aesthetics overlap, not because it belongs to the same chemical class.

How long does Botox last? For glabellar lines — the frown lines between the eyebrows — the label puts the duration of effect at approximately 3 to 4 months, with chemical denervation of the injected muscles beginning one to two days after injection and building through the first week (Botox Cosmetic prescribing information). The effect fades because nerve terminals regenerate and form new connections, not because the toxin is metabolised away on a schedule.

What is botulinum toxin actually approved for besides wrinkles? Rather a lot. The therapeutic Botox label covers overactive bladder and detrusor overactivity from a neurologic condition, neurogenic detrusor overactivity in children five and older, chronic migraine prophylaxis (defined as 15 or more headache days a month), spasticity in patients two and older, cervical dystonia, severe primary axillary hyperhidrosis, and blepharospasm and strabismus (Botox prescribing information). The label records an initial US approval of 1989 — more than a decade before the cosmetic use most people associate with it.

Why aren't units interchangeable between brands? Because a "Unit" is a result, not a quantity. One Unit of Botox corresponds to the calculated median intraperitoneal lethal dose in mice under that manufacturer's own assay, with its own vehicle, dilution scheme, and laboratory protocol — and every product defines its Unit against its own assay. The labels state that Units of one product cannot be compared to nor converted into Units of any other. Botox's own specific activity works out to roughly 20 Units per nanogram of neurotoxin complex, which is why a conversion table would be actively dangerous rather than merely inconvenient.

What is the boxed warning? Distant spread of toxin effect. Every botulinum toxin product carries it: effects may spread from the injection site to produce generalised muscle weakness, double vision, drooping eyelids, difficulty swallowing, voice changes, urinary incontinence, and breathing difficulty, hours to weeks after injection, with reports of death. The label notes the risk is probably greatest in children treated for spasticity, and that no definitive serious spread events have been reported at labeled cosmetic doses — 20 Units for glabellar lines, 24 for lateral canthal lines. Serious reactions including aspiration pneumonia have been reported specifically in unapproved uses.

Does counterfeit Botox actually cause harm? Yes, documented and recent. In March 2024 clinicians in Tennessee and New York City reported seven women with ptosis and dry mouth after cosmetic botulinum toxin injections, along with dysphagia, shortness of breath, weakness, blurred and double vision, and voice changes. Four were hospitalised and two went to intensive care. Every injection had been given by an unlicensed person — six in private residences, one at a cosmetic spa — and the FDA confirmed the product used in the Tennessee and Kentucky cases was counterfeit (Thomas et al., MMWR 2024;73:609–611). This is the concrete version of the abstract warning about informal sourcing.

Is botulinum toxin banned in sport? It is not named on the WADA Prohibited List, and it is not treated as a performance-enhancing substance — its pharmacology weakens muscle rather than strengthening it. Athletes remain responsible for confirming current status with their governing body, since list wording changes annually.